Imperial College London
Portrait Picture

Dr Oliver (OJ) Watson

Faculty of Medicine, School of Public Health

Lecturer
 
 
 
//

Contact

 

o.watson15

 
 
//

Location

 

Translation & Innovation Hub BuildingWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hogan:2022:10.1101/2022.01.17.22269222,
author = {Hogan, AB and Wu, SL and Doohan, P and Watson, OJ and Winskill, P and Charles, G and Barnsley, G and Riley, EM and Khoury, DS and Ferguson, NM and Ghani, AC},
doi = {10.1101/2022.01.17.22269222},
title = {The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant},
url = {http://dx.doi.org/10.1101/2022.01.17.22269222},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - <jats:title>Abstract</jats:title><jats:p>Vaccines have played a central role in mitigating severe disease and death from COVID-19 in the past 12 months. However, efficacy wanes over time and this loss of protection is being compounded by the emergence of the Omicron variant. By fitting an immunological model to population-level vaccine effectiveness data, we estimate that neutralizing antibody titres for Omicron are reduced by 3.9-fold (95% CrI 2.9–5.5) compared to the Delta variant. Under this model, we predict that 90 days after boosting with the Pfizer-BioNTech vaccine, efficacy against severe disease (admission to hospital) declines to 95.9% (95% CrI 95.4%–96.3%) against the Delta variant and 78.8% (95% CrI 75.0%–85.1%) against the Omicron variant. Integrating this immunological model within a model of SARS-CoV-2 transmission, we demonstrate that the size of the Omicron wave will depend on the degree of past exposure to infection across the population, with relatively small Omicron waves in countries that previously experienced a large Delta wave. We show that booster doses can have a major impact in mitigating the epidemic peak, although in many settings it remains possible that healthcare capacity could still be challenged. This is particularly the case in “zero-COVID” countries where there is little prior infection-induced immunity and therefore epidemic peaks will be higher. Where dose supply is limited, targeting boosters to the highest risk groups to ensure continued high protection in the face of waning immunity is of greater benefit than giving these doses as primary vaccination to younger age-groups. In many settings it is likely that health systems will be stretched, and it may therefore be necessary to maintain and/or reintroduce some level of NPIs to mitigate the worst impacts of the Omicron variant as it replaces the Delta variant.</jats:p>
AU  - Hogan,AB
AU  - Wu,SL
AU  - Doohan,P
AU  - Watson,OJ
AU  - Winskill,P
AU  - Charles,G
AU  - Barnsley,G
AU  - Riley,EM
AU  - Khoury,DS
AU  - Ferguson,NM
AU  - Ghani,AC
DO  - 10.1101/2022.01.17.22269222
PY  - 2022///
TI  - The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant
UR  - http://dx.doi.org/10.1101/2022.01.17.22269222
ER  -
Download